Study: Conventional Mammography ‘Likely’ Misses More Than 50 Percent of Breast Cancer Diagnoses
Emerging research from the RSNA conference suggests that two-dimensional mammography would only detect 41 percent of detectable breast cancer.
Relying solely on two-dimensional (2D) mammography may miss up to 59 percent of detectable breast cancer, according to new research presented at the Radiological Society of North America (RSNA) conference.1
For the research, study author Matthew Covington, MD considered 40,538,610 screening mammograms performed in 2023 based off Mammography Quality Standards Act (MQSA) data, a 43 percent prevalence of dense breasts, according to the Breast Cancer Surveillance Consortium (BCSC), and an estimated 17,431,602 supplemental screening exams.
Noting 469,437 detectable cases of breast cancer in the 2023 screening population, Dr. Covington proceeded to compare the proportions of breast cancer detection for 2D mammography, digital breast tomosynthesis (DBT), ultrasound, molecular breast imaging (MBI), contrast-enhanced mammography (CEM) and magnetic resonance imaging (MRI). For these estimates, Dr. Covington noted a CDR of 4.7/1000 cases for 2D mammography based on BCSC data and utilized previously reported incremental cancer detection rates (ICDRs) for DBT (1.7/1000), 2.7/1000 for ultrasound, 8.1/1000 for MBI, 10.7/1000 for CEM and 16/1000 for MRI.1,2
The research revealed that 2D mammography would diagnose an estimated 190,531 out of 469,437 cases of breast cancer (41 percent).
New research estimates, presented at the RSNA conference, suggest that conventional two-dimensional mammography may only diagnose 41 percent of detectable breast cancer. (Photo courtesy of Adobe Stock.)
“It is likely that 2D mammography identifies less than half of all detectable cancers within the screening population,” noted Dr. Covington, an assistant professor affiliated with the Department of Radiology and Imaging Sciences at the University of Utah.
(Editor’s note: For related coverage from RSNA, click here.)
Dr. Covington emphasized that supplemental breast MRI would provide the most optimal detection of breast cancer in women with dense breasts. Supplemental CEM was estimated to diagnose 80 percent of breast cancer (377,049/469,437) and supplemental MBI may offer a 71 percent detection rate (331,727/469,437), according to the study.1
The study results indicated that supplemental DBT and ultrasound would be less effective with estimates of 47 percent and 51 percent, respectively, for detectable breast cancers.1
“Evaluating the efficacy of different breast cancer screening methods, inclusive and exclusive of supplemental dense breast screening, could offer significant insights for devising effective screening strategies,” maintained Dr. Covington.
References
1. Covington M. Maximizing breast cancer detection: a comparative analysis of screening strategies. Poster presented at the Radiological Society of North America (RSNA) 2024 110th Scientific Assembly and Annual Meeting Dec. 1-5, 2024. Available at: https://www.rsna.org/annual-meeting .
2. Berg WA, Rafferty EA, Friedewald SM, Hruska CB, Rahbar H. Screening algorithms in dense breasts: AJR expert panel narrative review. AJR Am J Roentgenol. 2021:216(2):275-294.
Recent Videos
Related Content
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025Article
In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Podcast
Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
RSNA 2020: Addressing Healthcare Disparities and Access to Care
December 4th 2020Podcast
Rich Heller, M.D., with Radiology Partners, and Lucy Spalluto, M.D., with Vanderbilt University School of Medicine, discuss the highlights of their RSNA 2020 session on health disparities, focusing on the underlying factors and challenges radiologists face to providing greater access to care.
SNMMI: Can Multimodal Monitoring Bolster Outcomes with Pluvicto in Treating mCRPC?
June 22nd 2025Article
Multimodal treatment monitoring, including SPECT/CT exams 24 hours after treatment with Lu-177 PSMA-617, may have facilitated significantly shorter therapy durations and reduced side effects in patients with mCRPC, according to a two-year study presented at the Society for Nuclear Medicine and Molecular Imaging (SNMMI) conference.
GE HealthCare Unveils Enhanced LesionID Pro at SNMMI Conference
Published: June 21st 2025 | Updated: June 21st 2025Article
Emphasizing a zero-click experience, the updated LesionID Pro software, to be introduced at the SNMMI conference, reportedly provides AI-powered automated insights into whole-body tumor burden with PET and SPECT imaging.
